Pargari, M., Marahel, F., and Mombeni Goodajdar, B., J
OR Oral: 500mcg capsules for a 30-day cycle Administration Route: Subcutaneous injection for systemic healing Intramuscular injection for targeted healing Orally for gut healing or convenience Again, you can click here for dosing/reconstituting instructions
Common Side Effects (Generally Mild): Temporary injection site reactions (redness, slight swelling) Mild fatigue initially (as metabolism adjusts) Occasional flushing or warmth Slight changes in appetite Contraindications and Precautions: Pregnancy or breastfeeding (insufficient safety data) Active cancer (theoretical concerns about growth pathways) Severe kidney or liver disease (requires monitoring) Hypoglycemia risk (monitor if on diabetes medications) Medical Monitoring: At The Lamkin Clinic, we monitor MOTS-C patients with: Baseline metabolic labs (glucose, HbA1c, insulin, lipids) Follow-up testing at 8-12 weeks Body composition analysis Assessment of symptoms and energy levels Adjustment of other medications as metabolism improves Important: MOTS-C should only be used under the guidance of a qualified healthcare provider experienced in peptide therapy
This receptor complementarity is the basis for combined CJC-1295/Ipamorelin research protocols
CJC 1295 has a longer duration of action and helps maintain elevated GH and IGF-1 levels
Tesamorelin also has an acetyl group (CHCO-) attached to its N-terminus, which may potentially enhance the stability and bioactivity of the peptide
